Angiotensin receptor blockers in nephroprotection at patients with diabetes mellitus: focus on losartan
Many large studies have provided strong evidence that there is an association of elevated BP with a risk for cardiovascular events (CVE), such as stroke, myocardial infarction and heart failure. But none of the studies has indicated that a drug is more effective than another one in reducing the risk...
Main Authors: | Ol'ga Konstantinovna Vikulova, Marina Vladimirovna Shestakova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IP Morozov P.V.
2009-09-01
|
Series: | Системные гипертензии |
Subjects: | |
Online Access: | https://syst-hypertension.ru/2075-082X/article/view/33072 |
Similar Items
-
ANGIOTENSIN II RECEPTOR ANTAGONISTS AND NEPHROPROTECTION: PLACE OF OLMESARTAN
by: V. V. Fomin
Published: (2013-08-01) -
The use of angiotensin receptor blocker losartan in the combinational therapy of arterial hypertension
by: N Sh Zagidullin, et al.
Published: (2009-12-01) -
Renin-angiotensin-aldosterone system blockers as the main pathogenetic approach of drug nephroprotection
by: N.D. Filipets, et al.
Published: (2019-02-01) -
The role of angiotensin receptor antagonists in treatment of arterial hypertension: focus on losartan
by: Galina Anatol'evna Baryshnikova, et al.
Published: (2009-03-01) -
Immunomodulating, metabolic and cardioprotective effects of AT1-angiotensin receptors blocker losartan in patients with coronary heart disease and type 2 diabetes mellitus
by: A T Teplyakov, et al.
Published: (2009-03-01)